Chang Yuan, Zhou Lin, Xu Le, Fu Qiang, Yang Yuanfeng, Lin Zongming, Xu Jiejie
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Urol Oncol. 2017 Dec;35(12):675.e17-675.e24. doi: 10.1016/j.urolonc.2017.08.019. Epub 2017 Sep 13.
Accumulating evidence indicates that CXC chemokine receptor 6 (CXCR6) has a crucial role in cancer development and progression, however, its role in clear cell renal cell carcinoma (ccRCC) remains obscure. The aim of this study is to investigate the prognostic value of CXCR6 expression in patients with ccRCC following surgery.
This study retrospectively included 239 patients with ccRCC who underwent nephrectomy and had paraffin tissue available at a single center. CXCR6 expression in tumor tissue was evaluated by immunohistochemistry and its associations with overall survival (OS) and recurrence-free survival (RFS) were investigated.
A total of 47.3% tumors were considered as high expression of CXCR6, which was significantly associated with the male sex (P = 0.003) and high Fuhrman grade (P<0.001). A high expression of CXCR6 indicated a reduced OS (P<0.001) and RFS (P = 0.007). Multivariate analysis demonstrated that CXCR6 expression was an independent prognostic factor of OS (hazard ratio = 2.604; 95% CI: 1.338-5.068; P = 0.005) and RFS (hazard ratio = 1.957; 95% CI: 1.065-3.595; P = 0.031). Subgroup analysis found that CXCR6 expression could differentiate survival risks among patients with high-risk disease. Moreover, a nomogram integrating CXCR6 expression and traditional clinical and pathologic features was established and predicted postsurgical recurrence-risk well at 3- and 5-year.
The expression of CXCR6 in tumor tissue may serve as a potential prognostic biomarker to refine clinical prognosis prediction combined with traditional clinical and pathological analysis for patients with ccRCC after surgery.
越来越多的证据表明，CXC趋化因子受体6（CXCR6）在癌症的发生和发展中起关键作用，然而，其在透明细胞肾细胞癌（ccRCC）中的作用仍不清楚。本研究旨在探讨CXCR6表达对ccRCC患者术后的预后价值。
本研究回顾性纳入了239例在单一中心接受肾切除术且有石蜡组织的ccRCC患者。通过免疫组织化学评估肿瘤组织中CXCR6的表达，并研究其与总生存期（OS）和无复发生存期（RFS）的相关性。
共有47.3%的肿瘤被认为CXCR6高表达，这与男性（P = 0.003）和高Fuhrman分级（P<0.001）显著相关。CXCR6高表达表明OS（P<0.001）和RFS（P = 0.007）降低。多因素分析表明，CXCR6表达是OS（风险比=2.604；95%可信区间：1.338 - 5.068；P = 0.005）和RFS（风险比=1.957；95%可信区间：1.065 - 3.595；P = 0.031）的独立预后因素。亚组分析发现，CXCR6表达可区分高危疾病患者的生存风险。此外，建立了一个整合CXCR6表达以及传统临床和病理特征的列线图，该列线图对术后3年和5年的复发风险预测良好。
肿瘤组织中CXCR6的表达可能作为一种潜在的预后生物标志物，结合传统临床和病理分析，优化ccRCC患者术后的临床预后预测。
